Terray Therapeutics alternatives and competitors

PostEra is the medicinal chemistry counterpart to the biology platforms that dominate this category. Where Immunai, Cellarity and Enveda build models of cells, tissue or natural product chemistry to decide what to make, PostEra builds models of how to make it.

Superluminal Medicines chases the same target class as Nabla Bio and Antiverse and attacks it from the opposite direction.

Cellarity is a Flagship Pioneering company in Somerville, Massachusetts, founded in 2019, that designs drugs against the behavior of a whole cell rather than against a molecular target.

Variational AI develops Enki, a generative model for designing small molecules against a research team's target product profile.

Stanford spinout, now trading as Genesis Molecular AI, building GEMS, a small molecule discovery platform its own chemists and its partners' programs run on.

Numerion Labs, formerly known as Atomwise, is a San Francisco AI drug discovery company developing small molecules for immune and inflammatory disease, led by chief executive Steve Worland.

Chemify makes the molecules it designs, in a laboratory it built itself. Rather than handing a design to somebody with a laboratory, it is trying to turn its own laboratory into a printer.

Lila Sciences makes very large claims about what its platform can do, and as of September 2026 it has begun publishing evidence for some of them.

Aqemia designs small molecule drug candidates with Qemi, a platform that joins physics based prediction of how tightly a molecule binds its target with generative AI that proposes new molecules.

Deep Genomics is a Toronto AI drug discovery company launched in 2015 by Brendan Frey out of his University of Toronto work on the genetic determinants of disease.